Karen Knudsen: Science in Action – Men with Advanced Prostate Cancer Benefit
Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn about a paper by Neeraj Agarwal et al. published in The Lancet:
“Really enthusiastic about these positive findings, and the confirmation of what we hypothesized early on, based on the science of PARP1 function and AR crosstalk.
Even in 2012, when we first reported the preclinical modeling for combined AR and PARP targeting (Schiewer et al., Cancer Discovery), we were bullish about clinical utility (‘The combined studies highlight the importance of dual PARP-1 function in malignancy and provide the basis for therapeutic targeting’).
Of course, it took a village to bring the trials to life, but this is science in action, and in this case, men with advanced prostate cancer benefit. Well done, Neeraj Agarwal, MD, FASCO and GU colleagues!”
Title: Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Authors: Neeraj Agarwal, Arun A Azad, Joan Carles, André P Fay, Nobuaki Matsubara, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Prof Robert J Jones, Neal D Shore, Fred Saad, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G Healy, Matko Kalac, Dana Kennedy, Karim Fizazi
You can read the Full Article in The Lancet.
More posts featuring Karen Knudsen on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023